It’s not even a secondary battery, but it surges 979.37%… Future industry desired by experts

Shares of JLK, a medical AI (artificial intelligence) company스포츠토토, soared 979% this year. Not only JLK, but also medical AI companies such as Lunit, Vuno, and Selvas Healthcare jumped more than 380% this year. Experts predicted that medical AI is likely to grow in the future, and that it will continue the baton of secondary batteries.

According to the Korea Exchange on the 11th, JLK’s stock price has risen 979.37% this year. Among domestic listed stocks, the rate of increase is the second highest after Ecopro.

JLK is a company that provides a solution for diagnosing stroke through AI . This year, for the first time among AI solutions, it passed the integrated examination for innovative medical devices and became eligible for non-reimbursement insurance.

Kim Kyu-sang, a researcher at Hana Securities, said, “ JBS-01K is expected to receive a code for insurance application after completion of the demonstration project within the third quarter.” ” was expected. “In addition ,

JLK, together with two partners in the United States ,”NTAP (New Technology Additional Payment Compensation Scheme) is in the process of being approved,” he said. ” We expect a significant increase in corporate value upon FDA approval.” An AI

cancer diagnosis platform that reads medical image data and a platform that predicts cancer treatment response rates. Share prices of Lunit, which owns , also rose 466.11% this year, while AI medical companies Vuno, Selvas Healthcare, and Geninus rose 468.11%, 383.42%, and 145.22% this year. Medical AI companies have continued to rise until recently . Over the past month, Lunit has slightly slowed down, down 3.60%, but shares of JLK (up 113.84%), Vuno (21.40%), Selvas Healthcare (55.08%), and Geninus (66.46%) jumped . Experts cite medical AI as a future industry to pay attention to besides secondary batteries because the growth rate of medical AI has accelerated since the emergence of chat GPT , a generative AI . older brother AI

With the advent of , it is developing into a form that derives its own results. If the main function of medical AI in the past was similar to guidelines in the form of determining the most suitable treatment option, the emergence of generative AI has improved to a form with the ability to self-learn medical records and grasp the evidence of clinical results.

Kim Doo-hyun, a researcher at Hana Securities, said, “ The low reliability of AI solutions due to insufficient technology, which served as a hurdle for the growth of medical AI in the past, and difficulties in government regulation and health insurance registration are improving.” In response, the growth of domestic medical AI companies is expected to materialize thanks to the current government’s active policy support.” In particular , as Korea is an IT (information technology) powerhouse , expectations are high that it will grow globally in the medical AI field. Lunit has already formed partnerships with global medical device companies such as GE Healthcare, Philips, and Japan’s Fujifilm. Samsung Active Asset Management and Timefolio Asset Management are successively launching ETFs (Exchange Funds) that invest in medical AI and domestic bio companies.

There is a prospect that AI stock will be positive.

Researcher Kim said, “The time when stock prices were formed with expectations for an innovative technology called AI is already in the past. “

Leave a Reply

Your email address will not be published. Required fields are marked *